Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print June 11, 2007, 10.1148/radiol.2442060371
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2442060371v1
244/2/449    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Persigehl, T.
Right arrow Articles by Bremer, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Persigehl, T.
Right arrow Articles by Bremer, C.
(Radiology 2007;244:449-456.)
© RSNA, 2007

Experimental Studies

Antiangiogenic Tumor Treatment: Early Noninvasive Monitoring with USPIO-enhanced MR Imaging in Mice1

Thorsten Persigehl, MD, Ralf Bieker, MD, Lars Matuszewski, MD, Alexander Wall, MD, Torsten Kessler, MD, Hendrik Kooijman, PhD, Norbert Meier, PhD, Wolfgang Ebert, PhD, Wolfgang E. Berdel, MD, Walter Heindel, MD, Rolf M. Mesters, MD, and Christoph Bremer, MD

1 From the Departments of Clinical Radiology (T.P., L.M., A.W., N.M., W.H., C.B.) and Medicine/Hematology and Oncology (R.B., T.K., W.E.B., R.M.M.), University Hospital Muenster, Albert-Schweitzer-Str 33, D-48129 Muenster, Germany; Philips Medical Systems, Hamburg, Germany (H.K.); Bayer Schering Pharma, Berlin, Germany (W.E.); and Interdisciplinary Center for Clinical Research (IZKF Muenster, FG3), University of Muenster, Muenster, Germany (C.B.). From the 2004 RSNA Annual Meeting. Received February 27, 2006; revision requested April 27; revision received July 10; accepted August 7; final version accepted December 4. Supported in part by the German Research Foundation (BR 1653/2-1) and the Federal Ministry of Education and Research, Germany (13N8896). Address correspondence to C.B. (e-mail: bremerc{at}uni-muenster.de).

Purpose: To prospectively investigate steady-state blood volume measurements for early quantitative monitoring of antiangiogenic treatment with ultrasmall superparamagnetic iron oxide (USPIO)–enhanced magnetic resonance (MR) imaging.

Materials and Methods: The institutional animal care committee approved all experiments. HT-1080 fibrosarcoma-bearing nude mice were injected with a thrombogenic vascular targeting agent (VTA) (11 nude mice, 20 tumors) or saline (12 nude mice, 20 tumors). USPIO-enhanced (SH U 555C) MR imaging was performed after the VTA was administered. USPIO-induced changes in tissue R2* ({Delta}R2*) were measured with a T2-weighted dual-echo echo-planar imaging sequence, and the vascular volume fraction (VVF) was calculated. Parametric {Delta}R2* maps were analyzed with respect to tumor perfusion patterns. Correlative histologic analysis was performed for grading of tissue thrombosis, and tissue perfusion was quantified with fluorescent microbeads. Unpaired Student t test and Spearman nonparametric correlation coefficient were used for statistical analysis.

Results: The {Delta}R2* values were significantly (P < .001) reduced shortly after treatment initiation (mean {Delta}R2*, 0.017 msec–1 ± 0.0014 [standard error] in control animals vs 0.005 msec–1 ± 0.0007 in animals that received VTA), which was also reflected by a decrease in the VVF (2.47% ± 0.18 vs 0.41% ± 0.48, P < .001). Histologic analysis revealed various degrees of tumor thrombosis after VTA treatment that correlated inversely with the {Delta}R2* values (r = –0.83). Moreover, tumor perfusion measurements corroborated the MR results, indicating a significant reduction in tissue perfusion after VTA treatment (mean tissue fluorescence, 570.4 arbitrary units [au] per gram ± 27 vs 161.7 au/g ± 17; P < .05).

Conclusion: USPIO-enhanced MR imaging enables early monitoring of antiangiogenic treatment of tumors.

© RSNA, 2007




This article has been cited by other articles:


Home page
 Cancer Res.Home page
M. Palmowski, J. Huppert, P. Hauff, M. Reinhardt, K. Schreiner, M. A. Socher, P. Hallscheidt, G. W. Kauffmann, W. Semmler, and F. Kiessling
Vessel Fractions in Tumor Xenografts Depicted by Flow- or Contrast-Sensitive Three-Dimensional High-Frequency Doppler Ultrasound Respond Differently to Antiangiogenic Treatment
Cancer Res., September 1, 2008; 68(17): 7042 - 7049.
[Abstract] [Full Text] [PDF]